# Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma

*PRI Rank #20 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-20*

| Field | Value |
| --- | --- |
| Rank | #20 |
| 18m citations | 39 |
| Journal | Thyroid |
| Year | 2024 |
| DOI | 10.1089/thy.2023.0573 |
| Corresponding authors | Maria E. Cabanillas |
| Institution | The University of Texas MD Anderson Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1089/thy.2023.0573](https://doi.org/10.1089/thy.2023.0573)

## Topics

BRAF V600E mutation · Anaplastic thyroid carcinoma · dabrafenib · trametinib · pembrolizumab · immune checkpoint inhibitors · anti-PD-1 inhibitor · spartalizumab · BRAF/MEK inhibitors · neoadjuvant therapy · overall survival · progression-free survival · Drug resistance · immune-related adverse events · combination immunotherapy · hepatitis · colitis

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```